Home / Contract Awards / Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

Jeff Brody

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.

HHS said Wednesday its Biomedical Advanced Research and Development Authority will provide technical services and funds to help Paratek carry out research and manuacturing efforts for the Nuzyra drug, generically known as omadacycline.

The contract marks the department's first award under Project BioShield, which incentivizes pharmaceutical companies to produce medical products meant to help the government counter biological, chemical, radiological and nuclear threats.

The Food and Drug Administration approved oral and intravenous forms of Nuzyra for adults who suffer from community-acquired pneumonia and acute skin infection.

Boston-based Paratek aims to secure emergency use authorization for antibiotic treatment of anthrax lung infections. BARDA will buy an initial supply if the company obtains FDA approval for expanded use of the drug.

Check Also

Caddell-Nan JV to Build US Marine Quarters Under Potential $110M Contract

A joint venture between Caddell Construction and Hawaii-based Nan has won a potential $110.4M contract from the U.S. Navy to build bachelor-enlisted quarters at Naval Base Guam. The JV will design and construct a building complex with multiple floors on Joint Region Marianas site to house unaccompanied U.S. Marines, the Department of Defense said Wednesday.

Lockheed Secures Potential $113M IDIQ to Maintain Navy MUOS Satcom Network

The U.S. Navy has awarded Lockheed Martin’s (NYSE: LMT) space systems business a potential 10-year, $112.7M contract to help maintain a satellite system built to support military communications across the world.